Insider transactions
Travere Therapeutics NASDAQ:TVTX Chief Medical Officer Jula Inrig executed the sale of 8,233 shares of the company’s common stock over two trading days, April 14 and April 15, 2026, generating approximately $345,893 in proceeds. The shares changed hands in a price band from $41.9288 to $42.61, according to the company’s Form 4 filed with the Securities and Exchange Commission.
Per the same filing, Inrig also received 14,000 shares of Travere Therapeutics common stock at no cost on April 13, 2026, following the vesting of performance restricted stock units, or PSUs. A portion of the shares sold on April 14 and April 15 was used to satisfy tax obligations tied to the PSUs that vested on April 13.
One of the dispositions, the sale of 1,018 shares on April 15, was executed under a pre-established 10b5-1 trading arrangement. After accounting for the April acquisitions and the subsequent disposals, Inrig directly holds 111,473 shares of Travere Therapeutics common stock.
Market context and valuation notes
The insider selling coincided with TVTX trading close to its 52-week high of $43.31. Over the last 12 months, the stock has appreciated approximately 181%.
Data cited from InvestingPro in the filing notes that the shares are viewed as trading below their Fair Value and that analysts continue to express a constructive stance. At the time of the filing, the stock was quoted at $40.95 and Travere’s market capitalization was reported at $3.77 billion.
Regulatory milestone and analyst reactions
In other corporate developments disclosed alongside the insider activity, Travere secured full approval from the U.S. Food and Drug Administration for Filspari, its therapy for focal segmental glomerulosclerosis, or FSGS, in both adult and pediatric patients aged 8 years and older. The approval designates Filspari as the first and only FDA-approved treatment for FSGS and permits its use in patients who do not have active nephrotic syndrome.
Following the FDA decision, several brokerages updated their outlooks and price targets for Travere. Stifel raised its price target to $43 from $31 while maintaining a Hold rating. Guggenheim lifted its target to $54 from $49 and kept a Buy rating in place. Cantor Fitzgerald reiterated an Overweight rating, highlighting the broad label that covers primary, genetic, and secondary FSGS patients. H.C. Wainwright reaffirmed a Buy rating with a $47 price objective. These analyst actions were noted as part of the market response to Filspari’s regulatory milestone.
What this means
The disclosed transactions document routine insider activity tied to equity comp vesting and tax-liability management, while the regulatory approval and subsequent analyst adjustments underscore a notable event for the company and stakeholders. The filings provide a snapshot of management ownership and timing of stock sales relative to material company news.